Seasoned finance executive brings more than 20 years of leadership experience across global commerci

Video webcast now available  here

Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net

U.S. stocks fell, but S&P 500 gained 0.4% for 3rd week. Wall Street analysts make new stock pick

Oncobiologics (NASDAQ: OTLK) said it is preparing for the U.S. commercial launch of LYTENAVA after t

enGene (NASDAQ: ENGN - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both

BTIG analyst Julian Harrison reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintai

Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript

Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular

Oncobiologics NASDAQ: OTLK said it is preparing for the U.S. commercial launch of LYTENAVA after the

Outlook Therapeutics (NASDAQ:OTLK) released third-quarter financial results and hosted an earnings c

Outlook Therapeutics, Inc. (OTLK) came out with a quarterly loss of $0.09 per share in line with the

Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.09) per share which met the anal

The only FDA-approved ophthalmic bevacizumab, LYTENAVA TM , addresses a significant need in the U.S.

CNN Fear & Greed index showed improved market sentiment, with S&P 500 hitting a new record h

Outlook Therapeutics, Inc. (NASDAQ:OTLK) will release its third quarter earnings report before the o

Outlook Therapeutics (NASDAQ: OTLK) to release Q3 earnings on Aug. 14. Analysts expect a loss of 8 c

Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regu

Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's

ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook

Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market

Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), a biopharmaceutical compa

ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook

Oncobiologics (NASDAQ: OTLK - Get Free Report) and Pasithea Therapeutics (NASDAQ: KTTA - Get Free Re

Outlook Therapeutics rallies 311.8% in three months as Lytenava's FDA approval boosts optimism ahead

Outlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a l

ISELIN, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biophar

OTLK heads into Q3 results with investors watching European Lytenava sales, U.S. launch plans and up

Outlook Therapeutics (OTLK) receives both FDA and European approval for LYTENAVA, targeting wet AMD,

Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-

HC Wainwright & Co. analyst Douglas Tsao maintains Outlook Therapeutics (NASDAQ:OTLK) with a

Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular

The FDA approved LYTENAVA by Outlook Therapeutics, marking the first ophthalmic bevacizumab for wet

Wall Street analysts upgrade GM, RIVN, OTLK, F, and MBLY. See their ratings on Benzinga's analys

BTIG analyst Julian Harrison upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and

Outlook Therapeutics said on Friday the ​U.S. Food and Drug Administration has ‌approved its drug fo

Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an

Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an

Outlook Therapeutics shares rose after the FDA accepted its resubmitted LYTENAVA BLA and set a July

Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the stand

Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ra

Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and

Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and

Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and